VYNE Relative Valuation
VYNE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VYNE is overvalued; if below, it's undervalued.
Historical Valuation
Vyne Therapeutics Inc (VYNE) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.89. The fair price of Vyne Therapeutics Inc (VYNE) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：0.37
Fair
-0.52
PE
1Y
3Y
5Y
Trailing
Forward
0.41
EV/EBITDA
Vyne Therapeutics Inc. (VYNE) has a current EV/EBITDA of 0.41. The 5-year average EV/EBITDA is 0.13. The thresholds are as follows: Strongly Undervalued below -2.37, Undervalued between -2.37 and -1.12, Fairly Valued between 1.38 and -1.12, Overvalued between 1.38 and 2.63, and Strongly Overvalued above 2.63. The current Forward EV/EBITDA of 0.41 falls within the Historic Trend Line -Fairly Valued range.
0.62
EV/EBIT
Vyne Therapeutics Inc. (VYNE) has a current EV/EBIT of 0.62. The 5-year average EV/EBIT is 0.00. The thresholds are as follows: Strongly Undervalued below -3.24, Undervalued between -3.24 and -1.62, Fairly Valued between 1.63 and -1.62, Overvalued between 1.63 and 3.25, and Strongly Overvalued above 3.25. The current Forward EV/EBIT of 0.62 falls within the Historic Trend Line -Fairly Valued range.
15.59
PS
Vyne Therapeutics Inc. (VYNE) has a current PS of 15.59. The 5-year average PS is 57.09. The thresholds are as follows: Strongly Undervalued below -37.89, Undervalued between -37.89 and 9.60, Fairly Valued between 104.58 and 9.60, Overvalued between 104.58 and 152.07, and Strongly Overvalued above 152.07. The current Forward PS of 15.59 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Vyne Therapeutics Inc. (VYNE) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.41. The thresholds are as follows: Strongly Undervalued below -5.32, Undervalued between -5.32 and -3.37, Fairly Valued between 0.54 and -3.37, Overvalued between 0.54 and 2.50, and Strongly Overvalued above 2.50. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.24
P/FCF
Vyne Therapeutics Inc. (VYNE) has a current P/FCF of -0.24. The 5-year average P/FCF is -0.86. The thresholds are as follows: Strongly Undervalued below -3.88, Undervalued between -3.88 and -2.37, Fairly Valued between 0.65 and -2.37, Overvalued between 0.65 and 2.15, and Strongly Overvalued above 2.15. The current Forward P/FCF of -0.24 falls within the Historic Trend Line -Fairly Valued range.
Vyne Therapeutics Inc (VYNE) has a current Price-to-Book (P/B) ratio of 0.37. Compared to its 3-year average P/B ratio of 0.51 , the current P/B ratio is approximately -27.99% higher. Relative to its 5-year average P/B ratio of 1.19, the current P/B ratio is about -68.95% higher. Vyne Therapeutics Inc (VYNE) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -180.96%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -161.24% , the current FCF yield is about -100.00% lower.
0.37
P/B
Median3y
0.51
Median5y
1.19
-308.49
FCF Yield
Median3y
-180.96
Median5y
-161.24
Competitors Valuation Multiple
The average P/S ratio for VYNE's competitors is 0.00, providing a benchmark for relative valuation. Vyne Therapeutics Inc Corp (VYNE) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 39.67%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of VYNE decreased by 88.83% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 121.00K to 169.00K.
The secondary factor is the Margin Expansion, contributed -56.27%to the performance.
Overall, the performance of VYNE in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Vyne Therapeutics Inc (VYNE) currently overvalued or undervalued?
What is Vyne Therapeutics Inc (VYNE) fair value?
How does VYNE's valuation metrics compare to the industry average?
What is the current P/B ratio for Vyne Therapeutics Inc (VYNE) as of Dec 05 2025?
What is the current FCF Yield for Vyne Therapeutics Inc (VYNE) as of Dec 05 2025?
What is the current Forward P/E ratio for Vyne Therapeutics Inc (VYNE) as of Dec 05 2025?